Viatris, Ocuphire Pharma Announce FDA Approval Of RYZUMVl

Viatris Inc. (VTRS) and Ocuphire Pharma, Inc. (OCUP) announced the FDA has approved RYZUMVI 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists or parasympatholytic agents.

Related Keywords

Ocuphire Pharma ,More Such Health News ,Viatris Eye Care Division ,Ocuphire Pharma Inc ,Viatris Inc ,Eye Care Division President Jeffrey Nau ,Fda ,Viatris ,